Publication: Viewpoint of a WHO Advisory Group Tasked to Consider Establishing a Closely-monitored Challenge Model of Coronavirus Disease 2019 (COVID-19) in Healthy Volunteers
dc.contributor.author | Myron M. Levine | en_US |
dc.contributor.author | Salim Abdullah | en_US |
dc.contributor.author | Yaseen M. Arabi | en_US |
dc.contributor.author | Delese Mimi Darko | en_US |
dc.contributor.author | Anna P. Durbin | en_US |
dc.contributor.author | Vicente Estrada | en_US |
dc.contributor.author | Euzebiusz Jamrozik | en_US |
dc.contributor.author | Peter G. Kremsner | en_US |
dc.contributor.author | Rosanna Lagos | en_US |
dc.contributor.author | Punnee Pitisuttithum | en_US |
dc.contributor.author | Stanley A. Plotkin | en_US |
dc.contributor.author | Robert Sauerwein | en_US |
dc.contributor.author | Sheng Li Shi | en_US |
dc.contributor.author | Halvor Sommerfelt | en_US |
dc.contributor.author | Kanta Subbarao | en_US |
dc.contributor.author | John J. Treanor | en_US |
dc.contributor.author | Sudhanshu Vrati | en_US |
dc.contributor.author | Deborah King | en_US |
dc.contributor.author | Shobana Balasingam | en_US |
dc.contributor.author | Charlie Weller | en_US |
dc.contributor.author | Anastazia Older Aguilar | en_US |
dc.contributor.author | M. Cristina Cassetti | en_US |
dc.contributor.author | Philip R. Krause | en_US |
dc.contributor.author | Ana Maria Henao Restrepo | en_US |
dc.contributor.other | Faculty of Tropical Medicine, Mahidol University | en_US |
dc.contributor.other | Regional Centre for Biotechnology | en_US |
dc.contributor.other | Centro para Vacunas en Desarrollo Chile | en_US |
dc.contributor.other | King Saud bin Abdulaziz University for Health Sciences | en_US |
dc.contributor.other | Ifakara Health Institute | en_US |
dc.contributor.other | Universitetet i Bergen | en_US |
dc.contributor.other | Wuhan Institute of Virology Chinese Academy of Sciences | en_US |
dc.contributor.other | Universidad Complutense de Madrid | en_US |
dc.contributor.other | Organisation Mondiale de la Santé | en_US |
dc.contributor.other | University of Melbourne | en_US |
dc.contributor.other | University of Rochester Medical Center | en_US |
dc.contributor.other | Universitätsklinikum und Medizinische Fakultät Tübingen | en_US |
dc.contributor.other | Bill and Melinda Gates Foundation | en_US |
dc.contributor.other | Wellcome Trust | en_US |
dc.contributor.other | Monash University | en_US |
dc.contributor.other | National Institute of Allergy and Infectious Diseases (NIAID) | en_US |
dc.contributor.other | Radboud Universiteit | en_US |
dc.contributor.other | University of Maryland School of Medicine | en_US |
dc.contributor.other | Food and Drug Administration | en_US |
dc.contributor.other | University of Pennsylvania | en_US |
dc.contributor.other | Johns Hopkins Bloomberg School of Public Health | en_US |
dc.contributor.other | WHO RandD Blueprint COVID-19 Vaccines Working Group | en_US |
dc.contributor.other | Centre de Recherches Médicales de Lambaréné | en_US |
dc.date.accessioned | 2022-08-04T09:23:31Z | |
dc.date.available | 2022-08-04T09:23:31Z | |
dc.date.issued | 2021-06-01 | en_US |
dc.description.abstract | WHO convened an Advisory Group (AG) to consider the feasibility, potential value, and limitations of establishing a closely-monitored challenge model of experimental severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and coronavirus disease 2019 (COVID-19) in healthy adult volunteers. The AG included experts in design, establishment, and performance of challenges. This report summarizes issues that render a COVID-19 model daunting to establish (the potential of SARS-CoV-2 to cause severe/fatal illness, its high transmissibility, and lack of a "rescue treatment"to prevent progression from mild/moderate to severe clinical illness) and it proffers prudent strategies for stepwise model development, challenge virus selection, guidelines for manufacturing challenge doses, and ways to contain SARS-CoV-2 and prevent transmission to household/community contacts. A COVID-19 model could demonstrate protection against virus shedding and/or illness induced by prior SARS-CoV-2 challenge or vaccination. A limitation of the model is that vaccine efficacy in experimentally challenged healthy young adults cannot per se be extrapolated to predict efficacy in elderly/high-risk adults. | en_US |
dc.identifier.citation | Clinical Infectious Diseases. Vol.72, No.11 (2021), 2035-2041 | en_US |
dc.identifier.doi | 10.1093/cid/ciaa1290 | en_US |
dc.identifier.issn | 15376591 | en_US |
dc.identifier.issn | 10584838 | en_US |
dc.identifier.other | 2-s2.0-85094964919 | en_US |
dc.identifier.uri | https://repository.li.mahidol.ac.th/handle/20.500.14594/78189 | |
dc.rights | Mahidol University | en_US |
dc.rights.holder | SCOPUS | en_US |
dc.source.uri | https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85094964919&origin=inward | en_US |
dc.subject | Medicine | en_US |
dc.title | Viewpoint of a WHO Advisory Group Tasked to Consider Establishing a Closely-monitored Challenge Model of Coronavirus Disease 2019 (COVID-19) in Healthy Volunteers | en_US |
dc.type | Review | en_US |
dspace.entity.type | Publication | |
mu.datasource.scopus | https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85094964919&origin=inward | en_US |